TCRT
No price yet
Announcements
Nothing here yet
Daily updates
- Alaunos Therapeutics Completes Acquisition of Velaris TherapeuticsOct 13, 2026
- Alaunos filed a patent application covering identification of neoantigen-reactive T-cell receptors, expanding IP around its legacy TCR-T discovery platform without new clinical, regulatory, or financing progress in its current obesity and metabolic-disorders focus.Sep 18, 2026
FDA designations
Nothing here yet